FOYA winners announced

Published: 21-Jan-2011
Manufacturing Finance

Six pharmaceutical manufacturing facilities in Europe and the US win award categories

Six pharmaceutical manufacturing facilities in Germany, Switzerland, Sweden, and the US have won category awards in the annual Facility of the Year Awards (FOYA). A seventh facility received an Honourable Mention.

Pfizer Health won the Facility of the Year Award for Operational Excellence at its Project Pegasus – Bio 7 manufacturing facility in Strängnäs, Sweden. This microbial drug substance production plant manufactures two legacy Pfizer hormone treatments, Genotropin and Somavert. Pfizer scientists developed a manufacturing process with virtually identical unit operations that could be used for both products.

Project Pegasus won this category for Pfizer’s ability to bring a new facility online with added capacity without increasing staff numbers or extending shift patterns. This was achieved by incorporating a high degree of flexibility into the facility design. The project team also minimised manual interactions in the process.

Control system recipes were developed that enhanced the efficiency of this biotech operation. Targeted output of the facility was previously 2 batches per week, but as a result of their focus on Operational Excellence, the facility currently has the capacity to produce 3.5 batches per week.

F. Hoffman – La Roche took the Process Innovation category award for its “MyDose” clinical supply facility in Kaiseraugst, Switzerland.

MedImmune won for Project Execution at its Frederick Manufacturing Center (FMC) expansion facility in Frederick, Maryland, US, while the Facility Integration category award went to Merck and Company for its Global Clinical Supplies Manufacturing, Packaging and Warehouse expansion project in Summit, New Jersey, US.

Novartis Vaccines and Diagnostics took the Equipment Innovation category award for its “MARS Project” facility in Marburg, Germany.

The sixth winner was Pfizer Manufacturing Deutschland, which won the Sustainability category for its SPRING & E-MAP (Strategic Plant Restructuring & Energy Master Plan) project in Freiburg, Germany.

Shire HGT received an Honourable Mention for its Project Atlas, Building 400 facility in Lexington, Massachusetts, US.

Now in its seventh year, the Facility of the Year Awards, sponsored by ISPE, Interphex and Pharmaceutical Processing magazine in the US, recognise state-of-the-art pharmaceutical manufacturing projects that incorporate new and innovative technologies to enhance the delivery of a quality project, as well as reduce the cost of producing medicines.

The Overall Facility of the Year award will be presented during ISPE’s 2011 Annual Meeting, which takes place from 6–9 November in Grapevine, Texas, US.

See more

You may also like

Manufacturing

Almac highlights SDS-PAGE approach for residual protein determination in new white paper

Read more
New white paper explores robust analytical method for residual protein detection in biocatalytic API manufacturing

Trending Articles

  1. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  2. Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
  3. Sun Pharma to acquire Organon in $11.75bn deal, expanding global manufacturing and biosimilars reach The firm will acquire Organon in an all-cash $11.75bn transaction, creating a larger global pharma group with expanded manufacturing capacity, stronger women's health operations and a top-10 biosimilars position
  4. Simplifying continuous operations: lowering the barrier to faster development Continuous manufacturing has long promised faster development, improved process understanding and, in the absence of scale-up, smoother commercialization. For many pharmaceutical R&D teams, those benefits are well understood. What still holds them back, however, is not scepticism about the concept; it’s the perceived effort required to implement it
  5. Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Almac highlights SDS-PAGE approach for residual protein determination in new white paper

New white paper explores robust analytical method for residual protein detection in biocatalytic API manufacturing
Manufacturing

Reliable, high-performance pump for HPLC and UHPLC

Biotech Fluidics announce the ASI 540 – an affordable, standalone solvent delivery pump - design optimised for liquid chromatography applications
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Britain's biotech potential (part II): world-class science, second-class support?

In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Finance

Sun Pharma to acquire Organon in $11.75bn deal, expanding global manufacturing and biosimilars reach

The firm will acquire Organon in an all-cash $11.75bn transaction, creating a larger global pharma group with expanded manufacturing capacity, stronger women's health operations and a top-10 biosimilars position
Manufacturing

Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform

The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
Finance

UK biotech venture capital rises 17% in Q1 2026 as deal activity surges 67% year-on-year, BIA figures show

Total UK biotech equity financing reached £552m in the first quarter of 2026, driven by a 17% quarterly rise in venture capital investment, according to BioIndustry Association data, though public markets remain dormant with no IPOs recorded since 2022
Subscribe now